Post by
HeebieJeebies on Oct 11, 2017 9:22am
Emblem Positioned to be Disruptive in Medical Cannabis
https://www.baystreet.ca/stockstowatch/2299/Emblem-Positioned-to-be-Disruptive-in-the-Medical-Cannabis-Industry
Comment by
ledrog on Oct 11, 2017 9:39am
For $4,000 they better write something good...
Comment by
deminimis on Oct 11, 2017 9:41am
They expect to begin selling the pain release medication by fall 2018? Damn, that is much sooner than I expected. Glad to see they are actually trying to promote the stock again.
Comment by
tarnoir on Oct 11, 2017 3:11pm
They need to get their grow room production going - expansion etc. In order to compete in this marketplace - they are a piss ant compared to the big 4.
Comment by
cressco on Oct 11, 2017 3:59pm
I thought the same thing, I guess pain studies aren't as time consuming. I also like this quote from the last news release: "......We are also looking forward to further collaborations with Canntab to bring other groundbreaking cannabis-based advanced dosage forms to the market." Regards
Comment by
cressco on Oct 11, 2017 5:04pm
Thanks for clarifying. Awful assumption on my behalf as I only skimmed through and the answer was right in the article. It does make sense that the reason would be the known side effect profile of cannabis.